If the data from the MAGNITUDE study is found to be positive, it will enable global regulatory filings for NTLA-2001. Image Source: Zacks Investment Research This apart, NTLA submitted a clinical trial application to initiate a first-in-human phase I study of NTLA-3001 in December 2023. The company plans to begin patient dosing later in 2024. Some better-ranked stocks in the healthcare sector are Acrivon Therapeutics, Inc. (ACRV) and Aligos Therapeutics, Inc. (ALGS) , each carrying a Zacks Rank #2 (Buy) at ...

Core Viewpoint - Intellia Therapeutics has appointed Brian Goff to its board of directors, bringing extensive experience in commercialization and operations within the biopharmaceutical industry, particularly in rare diseases [1][2][6]. Company Overview - Intellia Therapeutics, Inc. is a clinical-stage gene editing company focused on CRISPR-based therapies aimed at revolutionizing medicine. The company operates in vivo programs for precise gene editing within the human body and ex vivo programs for engineering human cells to treat cancer and autoimmune diseases [3]. Leadership Experience - Brian Goff has over three decades of experience in the biopharmaceutical sector, having held leadership roles at Agios Pharmaceuticals, Alexion Pharmaceuticals, Neurovance, and Baxalta. His expertise includes global commercialization and product launches for rare diseases [2][6]. Strategic Importance - The addition of Brian Goff to the board is seen as crucial for Intellia as it transitions from late-stage clinical development to commercialization of its CRISPR-based therapies for life-threatening diseases. His experience is expected to guide the company through this evolution [6].

CAMBRIDGE, Mass., June 14, 2024 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced the appointment of Brian Goff to its board of directors. Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies. The company's in vivo programs use CRISPR to enable precise editing of diseas ...

On June 2, Intellia Therapeutics' (NTLA -0.96%) CEO John Leonard remarked on the biotech's progress with one of its early-stage clinical programs called NTLA-2002, uttering two very important words that are sure to make at least a few savvy investors salivate. The stock briefly rose 8% above where it was before the announcement. This is a good omen Such patients might still technically have the disorder, as it is currently impossible for 100% of the copies of their genes, which are distributed across the my ...

Artur Plawgo Intellia Therapeutics (NASDAQ:NTLA) recently reported strong data from the Phase I portion of an ongoing Phase I/II study for NTLA-2002, an in vivo CRISPR-based gene editing therapy for hereditary angioedema (HAE). I have previously written about CRISPR Therapeutics (CRSP) and rated the company a strong buy due to its progress in the commercialization of Casgevy, an ex vivo CRISPR-based gene editing therapy. While CRISPR Therapeutics remains a strong buy, certain advantages of Intellia's therap ...

Intellia Therapeutics' (NTLA) shares gained 10% on Jun 3 after the company reported encouraging long-term data from the phase I portion of its early to mid-stage study evaluating NTLA-2002 for treating hereditary angioedema (HAE). Shares of NTLA continued to gain another 1.1% in the after-market hours. Image Source: Zacks Investment Research A total of 10 patients are being treated in the phase I portion of the study with either of the three one-time doses (25 mg, 50 mg, or 75 mg) of NTLA-2002,administered ...

NTLA has rallied 10.9% over the past four weeks, and the company is a Zacks Rank #3 (Hold) at the moment. This combination suggests NTLA could be on the verge of another move higher. Looking at NTLA's earnings estimate revisions, investors will be even more convinced of the bullish uptrend. There have been 8 higher compared to none lower for the current fiscal year, and the consensus estimate has moved up as well. From a technical perspective, Intellia Therapeutics, Inc. (NTLA) is looking like an interestin ...

Intellia Therapeutics, Inc. (NTLA) reported first-quarter 2024 loss of $1.06 per share, which was narrower than the Zacks Consensus Estimate of a loss of $1.35. In the year-ago quarter, Intellia incurred a loss of $1.17 per share.The reported loss excluded a one-time expense of change in fair value of investments, net, including which the company reported a loss of $1.12 per share in the first quarter of 2024.The company’s total revenues currently comprise only collaboration revenues. NTLA reported revenues ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 INTELLIA THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 36-4785571 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37766 (State or Other Jurisdiction ...

Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $1.06 per share versus the Zacks Consensus Estimate of a loss of $1.35. This compares to loss of $1.17 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 21.48%. A quarter ago, it was expected that this company would post a loss of $1.47 per share when it actually produced a loss of $1.46, delivering a surprise of 0.68%.Over the last four quarters, the company h ...